Surrozen IncDE
For the period ended Dec 31, 2023. Filed Apr 10, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| SURROZEN, INC. | ||
| Date: April 10, 2024 | By: | /s/ Craig Parker |
|---|---|---|
| Craig Parker | ||
| President and Chief Executive Officer and Director | ||
| (Principal Executive Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Craig Parker and Charles Williams, and each or any one of them, their true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-facts and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Craig Parker | President and Chief Executive Officer and Director | April 10, 2024 |
| Craig Parker | (Principal Executive Officer) | |
| /s/ Charles Williams | Chief Financial Officer and Chief Operating Officer | April 10, 2024 |
| Charles Williams | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ David J. Woodhouse, Ph.D. | Chair of the Board of Directors | April 10, 2024 |
| David J. Woodhouse, Ph.D. | ||
| /s/ Anna Berkenblit, M.D. | Director | April 10, 2024 |
| Anna Berkenblit, M.D. | ||
| /s/ Eric Bjerkholt | Director | April 10, 2024 |
| Eric Bjerkholt | ||
| /s/ Christopher Chai | Director | April 10, 2024 |
| Christopher Chai | ||
| /s/ Mary Haak-Frendscho, Ph.D. | Director | April 10, 2024 |
| Mary Haak-Frendscho, Ph.D. | ||
| /s/ Tim Kutzkey, Ph.D. | Director | April 10, 2024 |
| Tim Kutzkey, Ph.D. | ||
| /s/ Shao-Lee Lin, M.D., Ph.D. | Director | April 10, 2024 |
| Shao-Lee Lin, M.D., Ph.D. | ||
| /s/ Mace Rothenberg, M.D. | Director | April 10, 2024 |
| Mace Rothenberg, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.